Progress in Role of FEZF1-AS1 in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2020.101.05
- Author:
Jin CHEN
1
;
Rong YIN
2
;
Xinyin LIU
3
Author Information
1. Nanjing Medical University, Nanjing 211166, China.
2. Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China.
3. Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
- Publication Type:Journal Article
- Keywords:
FEZF1-AS1;
LncRNA;
Lung neoplasms
- From:
Chinese Journal of Lung Cancer
2020;23(4):294-298
- CountryChina
- Language:Chinese
-
Abstract:
Nowadays, accumulating evidence indicates that long non-coding RNA (lncRNA) play vital roles in tumorigenesis. As a newly discovered lncRNA, FEZ family zinc finger 1-antisense RNA 1 (FEZF1-AS1) is markedly upregulated in various malignant tumors including non-small cell lung cancer (NSCLC). Aberrant expression of FEZF1-AS1 is related to clinical characteristics of patients with NSCLC and suggests poor prognosis. Moreover, FEZF1-AS1 can regulate numerous biological processes, such as cell proliferation, migration and invasion through different mechanisms. In this article, we systematically summarize the recent research progress of FEZF1-AS1 in NSCLC, which might be a novel target for clinical therapy.
